^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Super NK cell therapy
i
Other names: Super NK cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Qihan Biotech
Drug class:
NK cell stimulant
Related drugs:
over1year
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=102, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
New P1 trial
|
CD33 (CD33 Molecule)
|
CD33 positive • CD33 expression
|
cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy
over2years
Off-the-Shelf iPSC-Derived Nature Killer Cells with Enhanced Expression of NK Activating Receptors for the Treatment of Solid Tumors (ASGCT 2022)
Here we report QN-030 (“Super NK cells”), an investigational, iPSC-derived NK cell product with enhanced expression of a variety of activating receptors (NKG2D and NCRs) intended for the treatment of solid tumors...Close monitoring of NKG2D/NCR expression revealed the potential mechanism of enhanced tumor killing activity. Together, we have engineered iPSC-derived QN-030 NK cells as a promising clinical drug candidate for treatment of solid tumors.
IO biomarker
|
IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
|
Super NK cell therapy
over2years
"Super NK cells" - natural killer cells derived from engineered hiPSC with enhanced NK receptor expression demonstrate better anti-tumor effects for solid tumors (AACR 2022)
More importantly, the “super NK cells” show improved cytotoxicity to multiple solid tumors in both in vitro system and in vivo xenograft mouse models. In summary, we have engineered hiPSCs which can be differentiated into "super NK cells" as a potential cell therapy product for improved efficacy against solid tumors.
IO biomarker
|
NKG2D (killer cell lectin like receptor K1)
|
Super NK cell therapy
Share via
